The company has enrolled 50% of the patients (i.e., ~147) in the P-III study evaluating the therapeutic effect, QoL & patient satisfaction of AKP02 for the treatment of mild/moderate psoriasis with results expected in Q3’22. Lipidor initiated recruitment in Jan’22
Lipidor will enroll a total of 294 patients with the last patient expected to initiate treatment in Jun’22. Additionally, Lipidor along with its commercial partner RELIFE are working on AKP01 & AKP02 for the treatment of the same indication in the EU, CIS countries & Turkey
AKP02 is a combination of calcipotriol + betamethasone dipropionate & is based on Lipidor’s AKVANO technology. Additionally, the company will evaluate AKP02 in comparison with Enstilar
Ref: Cision | Image: Lipidor
